Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Fimasartan/Amlodipine/Rosuvastatin FDC vs Co-administration
NCT02995720Phase 1Completed
- Sponsor
- Boryung
- Start
- Aug 2016
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of fimasartan, amlodipine and rosuvastatin in hypertension (HTN) and hyperlipidemia (2 arms), sponsored by Boryung. Primary endpoints: Maximum concentration of drug in plasma and Area Under the Curve from the dosing time to the last measurable concentration. Started Aug 2016; status: completed.
02
Drugs
fimasartanamlodipinerosuvastatin
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on NCT02995720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02995720.